Skip to main content
SpringerLink
Log in

Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases

  • Published:
Journal of Gastrointestinal Surgery

abstract

Degradable starch microspheres (DSMs) provide transient occlusion of small arteries and are thought to improve the therapeutic effect of anticancer drugs. Irinotecan (CPT-11) is one of the most effective anticancer agents. We herein report cases with liver metastases treated with transarterial chemoembolization with DSM, CPT-11, and mitomycin-C (DSM-CPT therapy). Five patients underwent DSM-CPT therapy for liver metastases that originated from colorectal cancer for four and gastric cancer for one. They all lack indication for surgery. They were all male with an age range of 42–78 years (mean, 55.2 years). Three of them had pretreatment histories with 5-fluorouracil or related agents, and four of them had combined systemic or local chemotherapy at the period. Required doses for stasis of whole blood flow of hepatic artery of DSMs were used with CPT-11 and mitomycin-C. After one to six injections, four patients had a partial response and the disease progressed in one patient with gastric cancer origin. Two of the partial response patients underwent surgery after 2 months of the partial response period. Carcinoembryonic antigen and CA19-9 levels in partial response patients decreased to 16.1% and 19.3% of the level before treatment, respectively. DSM-CPT therapy can be a potential therapy for liver metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chir Scand 1978;144:275–281.

    PubMed  CAS  Google Scholar 

  2. Lindell B, Aronsen KF, Rothman U. Repeated arterial embolization of rat livers by degradable microspheres. Eur Surg Res 1977;9:347–356.

    PubMed  CAS  Google Scholar 

  3. Sigurdson ER, Ridge JA, Daly JM. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch Surg 1986;121:1277–1281.

    Article  PubMed  CAS  Google Scholar 

  4. Aronsen KF, Hellekant C, Holmberg J, et al. Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugs. Eur Surg Res 1979;11:99–106.

    PubMed  CAS  Google Scholar 

  5. Dakhil S, Ensminger W, Cho K, et al. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer 1982;50:631–635.

    Article  PubMed  CAS  Google Scholar 

  6. Ensminger WD, Gyves JW, Stetson P, et al. Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res 1985;45:4464–4467.

    PubMed  CAS  Google Scholar 

  7. Taguchi T, Tanikawa K, Sano K, et al. Multi-Center cooperative phase II study of combined infusion of PJ-203 (degradable starch microspheres) into hepatic artery in metastatic liver cancer [in Japanese]. Gan To Kagaku Ryoho 1993;20:2015–2025.

    PubMed  CAS  Google Scholar 

  8. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 1994;26:275–291.

    PubMed  CAS  Google Scholar 

  9. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  10. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  11. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.

    Article  PubMed  CAS  Google Scholar 

  12. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  13. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11C 5-fluorouracil (5FU)/leucovorin (LV) or oxal C CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI Intergroup Study. ProcASCO 2002;21:511.

    Google Scholar 

  14. Conti JA, Kemeny NE, Saltz LB, et al. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995;75:769–774.

    Article  PubMed  CAS  Google Scholar 

  15. Ross P, Norman A, Cunningham D, et al. A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995–1001.

    Article  PubMed  CAS  Google Scholar 

  16. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604–610.

    Article  PubMed  CAS  Google Scholar 

  17. Villalona-Calero MA, Kuhn J, Drengler R, et al. Pharmacologically-based phase I study of mitomycin-C as a modulator of irinotecan antitumor activity. Proc ASCO 2001;20:400.

    Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216.

    Article  PubMed  CAS  Google Scholar 

  19. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896/2-903.

    Google Scholar 

  20. Kono A, Hara Y. Conversion of CPT-11 into SN-38 in human tissues. Gan To Kagaku Ryoho 1991;18:2175–2178.

    PubMed  CAS  Google Scholar 

  21. van Riel JM, van Groeningen CJ, de Greve J, et al. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004;15:59–63.

    Article  PubMed  Google Scholar 

  22. Fiorentini G, Rossi S, Dentico P, et al. Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003;89:382–384.

    PubMed  CAS  Google Scholar 

  23. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847–854.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukakecho, Toyoake, 470-1192, Aichi, Japan

    Zenichi Morise M.D., Ph.D., Atsushi Sugioka M.D., Ph.D., Ryoichi Kato M.D., Ph.D., Junko Fujita M.D., Ph.D., Sojun Hoshimoto M.D. & Takazumi Kato M.D.

Authors
  1. Zenichi Morise M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsushi Sugioka M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryoichi Kato M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junko Fujita M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sojun Hoshimoto M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takazumi Kato M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zenichi Morise M.D., Ph.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morise, Z., Sugioka, A., Kato, R. et al. Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. J Gastrointest Surg 10, 249–258 (2006). https://doi.org/10.1016/j.gassur.2005.08.004

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2005.08.004

Key words

Search

Navigation